Clinical trial NCT03752294: A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
Official title: A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Mild Cognitive Impairment
Mild Alzheimer's Disease
Keywords: MCI
Mild AD
Dabigatran
Lead sponsor: University of Rhode Island
Sponsor class: OTHER
Collaborators: name: Alzheimer's Drug Discovery Foundation
name: Boehringer Ingelheim
First posted: 2018-11-23
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized-control, Double-blind, Multicenter, Delayed-start, Pilot
Primary purpose: TREATMENT

Brief summary: A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs. placebo of dabigatran in men and women, between the ages of 50-85 years, confirmed with MCI probably due to AD and mild Alzheimer's Disease.

Detailed description: The study will be conducted in 2-phases. The Phase I double-blind portion of the study consists of 40-60 active participants with MCI probably due to AD and mild AD randomized to 150mg once-a-day dose of dabigatran or placebo. A futility analysis will be conducted based on month 3 plasma biomarker changes from baseline. Excluding futility, at the end of Phase I, the study continues onto the open-label phase of the study where the placebo arm will be treated with 150mg once-a-day with dabigatran from months 10-21. The active treatment arm will continue on dabigatran through month-21. For final analysis, a difference in intercept of a generalized growth model between randomization groups during Phase 2 in the Cognitive Dementia Rating Scale-Sum of Boxes (CDR-SB) will be taken as evidence of effectiveness and justify further study. All patients will discontinue dabigatran after month 21 and a 3-month follow-up period will confirm whether or not the proposed cognitive effects can be sustained in the absence of treatment. The relationships between changes in levels of plasma biomarkers over time will be tested with regards to each other and relative to MRI and cognitive testing performed at scheduled intervals.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of MCI likely due to AD or mild AD based on IWG-2 criteria for typical AD (A plus B at any stage) 2011 revised criteria
2. English speaking men \& woman age 50 -85 years (inclusive)
3. Ability to provide informed consent
4. MMSE score \>20 at screening
5. Informant or caregiver (e.g. family member, friend) willing to participate in semi-structured interviews
6. CSF Aβ positive (MCI and AD) or a positive amyloid positron emission tomography (PET) scan within 6-months prior to screening using IWG-2 criteria.
7. CDR Scale Global Score between 0.5 and 1
8. Stable dosing (prior 3-months) of standard AD medications are allowed
9. Demonstrated willingness to comply with study visit schedule, laboratory studies, and other study procedures

Exclusion Criteria:

1. Pre-menopausal women (last menstruation \< 1 year prior to screening) who are not surgically sterile.
2. Creatinine clearance \< 50mL/min
3. Current psychiatric or neurological disorder that would contribute to cognitive impairment (focal neurological features early extrapyramidal signs, early hallucinations, cognitive fluctuations, non-AD dementia, major depression)
4. Cerebrovascular disease
5. Toxic, inflammatory, and metabolic disorders, all of which may require specific investigations
6. MRI Flair or T2 signal changes in the medial temporal lobe that are consistent with infectious or vascular insults
7. Sudden onset or early occurrence of the following symptoms: gait disturbances, seizures, major and prevalent behavioral changes
8. Inability to swallow pills
9. Current anticoagulant therapy
10. Conditions associated with an increased risk of bleeding (e.g. major surgery within 30-days of baseline, planned surgery or intervention during treatment period)
11. History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding
12. Gastrointestinal hemorrhage within the past year
13. Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30-days; hemorrhagic disorder or bleeding diathesis
14. Need for anticoagulant treatment of disorders, fibrinolytic agents within 48-hours of study baseline, uncontrolled hypertension (systolic blood pressure greater than 180mm Hg and/or diastolic blood pressure greater than 100 mm Hg)
15. Recent malignancy or radiation therapy (within 6-months) and a survival rate of 3-years,
16. Active infective endocarditis
17. Active liver disease (including but not limited to persistent ALT, AST, Alk Phos greater than twice the upper limit of the normal range; active hepatitis C (positive HCV RNA)
18. Active hepatitis B (HBs antigen +, anti HBc IgM +), active hepatitis A
19. HIV/AIDS diagnosis

MRI exclusionary criteria

1. Brain Aneurysm Clip
2. Implanted neural stimulator
3. Implanted cardiac pacemaker or defibrillator
4. Cochlear implant
5. Ocular foreign body (e.g. metal shavings)
6. Other implanted medical devices: (e.g. Swan Ganz catheter, mechanical prosthetic heart)
7. Insulin pump
8. Metal shrapnel or bullet

Additional concomitant drug exclusionary criteria will be applied by investigator.

Primary outcomes:
measure: Evaluate dabigatran efficacy in MCI and mild AD population using changes in targeted plasma and CSF biomarker levels at 9 and 21 months
timeFrame: 9 and 21-months
Secondary outcomes:
measure: Demonstrate a reduction in decline of cognitive function related to physical functioning in placebo arm after crossing over to 12-months of active treatment
timeFrame: 12 - 24 months
measure: Changes in cognitive performance in placebo arm after cross-over to open-label treatment phase
timeFrame: 24-months
measure: Safety and tolerability of dabigatran in experimental population (MCI and mild AD populations) based on reported serious and adverse events
timeFrame: 21-months
measure: Evaluation of cognitive performance in placebo arm after cross-over to open-label treatment phase
timeFrame: 24-months
Other outcomes:
Locations:
Study officials:
affiliation: Executive Director of the Ryan Institute for Neuroscience
name: Paula Grammas, PhD
role: STUDY_DIRECTOR
affiliation: Medical Director, Rhode Island Mood & Memory Research Institute
name: John Stoukides, MD
role: PRINCIPAL_INVESTIGATOR
References: